Dr Quin Wills
Co-founder and Chief Scientific Officer of SimuGen Ltd
Quin's roots are in clinical medicine and genetics; more recently in the mathematical modelling of the genome. SimuGen was founded as a toxicogenomics company in Cambridge, with the vision that central to the debate around traditional toxicology is the enormous attrition rate of drugs. Quin and his team feel that better, high-throughput screens - before traditional toxicology - should be core to current progress. SimuGen uses models of how genes are expressed in human cell cultures as such an approach.